Not yet "case closed" on EU's human tissue product regulation?
This article was originally published in Clinica
There is still sufficient strong feeling among those representing medical device manufacturers over the regulation of human tissue engineered products (hTEPS) to suggest that the debate within the European Council on the European Commission's proposed Regulation for Advanced Therapy Products could be both lively and complex.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.